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The possibility of using gene therapy for the treatment of cancer is limited by the lack of safe, intravenously administered delivery
systems able to selectively deliver therapeutic genes to tumors. In this study, we investigated if the conjugation of the polypropylenimine
dendrimer to lactoferrin and lactoferricin, whose receptors are overexpressed on cancer cells, could result in a selective gene delivery to
tumors and a subsequently enhanced therapeutic efficacy. The conjugation of lactoferrin and lactoferricin to the dendrimer significantly
increased the gene expression in the tumor while decreasing the non-specific gene expression in the liver. Consequently, the intravenous
administration of the targeted dendriplexes encoding TNFα led to the complete suppression of 60% of A431 tumors and up to 50% of B16-
F10 tumors over one month. The treatment was well tolerated by the animals. These results suggest that these novel lactoferrin- and
lactoferricin-bearing dendrimers are promising gene delivery systems for cancer therapy.
From the Clinical Editor: Specific targeting of cancer cells should enhance the delivery of chemotherapeutic agents. This is especially true for gene
delivery. In this article, the authors utilized a dendrimer-based system and conjugated this with lactoferrin and lactoferricin to deliver anti-tumor genes.
The positive findings in animal studies should provide the basis for further clinical studies.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CCBY license (http://creativecommons.org/licenses/by/4.0/).
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therapy, the use of therapeutic genes in cancer treatment is still
limited by the lack of safe, intravenously administered delivery
systems able to carry therapeutic DNA selectively to the tumors,
without secondary effects to healthy tissues.1
In order to remediate to this problem, numerous non-viral
gene delivery systems are currently under development, due to
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Among these delivery systems, generation 3-diaminobutyric
polypropylenimine dendrimer (DAB) appears to be particularly
promising. We have recently demonstrated that the intravenous
administration of this dendrimer conjugated to transferrin (Tf),
whose receptors are overexpressed on cancer cells, resulted in
gene expression mainly in the tumors after intravenous
administration.4 Thus, DAB-Tf dendrimer complexed to a
TNFα-encoding DNA led to a rapid and sustained tumor
regression over one month, resulting in complete suppression of
90% of the tested A431 tumors and regression of the remaining
10%.4 Importantly, the treatment was well tolerated by the
animals, with no apparent signs of toxicity.
Building on this study, we now would like to develop a novel
gene-based therapeutic system with improved tumor targeting
and therapeutic efficacy. To do so, we propose to replace the
transferrin moiety by other promising tumor-targeting ligands of
the same family that have been shown to have intrinsic
anti-tumoral activity, such as lactoferrin and lactoferricin.ticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
nous administration of lactoferrin- and lactoferricin-bearing dendriplexes.
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members of the transferrin family, able to bind the transferrin
receptors. In addition to their tumor delivery properties, these
iron-carriers have recently been shown to have anti-cancer
properties themselves, which make them highly attractive as part
of a gene medicine.
LF has been shown to inhibit the proliferation of many cancer
cell lines through induction of cell cycle arrest and modulation of
the mitogen-activated protein kinase signaling pathway in vitro.5
The inhibition of tumor cell growth by LF may also be related to
the ability of this protein to induce apoptosis of cancer cells by
activating the Fas signaling pathway in cancerous cells.
Like LF, LFC has been shown to exert anti-tumor effects
against a number of cancer cell lines. LFC is a potent inducer of
apoptosis in various cancer types.6 LFC has also been reported to
exert potent in vivo anti-tumor activity in mouse models of
cancer. For example, direct injection of LFC into solid Meth A
tumors causes tumor cell lysis and reduction in tumor size.7 In
addition, subcutaneous administration of LFC inhibits tumor
metastasis by metastatic murine L5178Y-ML25 lymphoma cells
and B16-F10 melanoma cells.8 We therefore hypothesize that
using LF and LFC as tumor-targeted ligands could improve the
overall efficacy of the DAB delivery system.
The objectives of this study were therefore 1) to prepare and
characterize lactoferrin- and lactoferricin-bearing DAB dendri-
mers and 2) to evaluate their targeting and therapeutic efficacy on
cancer cells in vitro and in vivo after intravenous administration.Methods
Cell lines and reagents
Lactoferrin and lactoferricin, generation 3-diaminobutyric
polypropylenimine dendrimer (DAB) and the other chemicals
were purchased from Sigma Aldrich (Poole, UK). The expression
plasmids encoding Tumor necrosis factor (TNF) α (pORF9-
mTNFα) and β-galactosidase (pCMVsport β-galactosidase) were
obtained respectively from InvivoGen (San Diego, CA) and
Invitrogen (Paisley, UK) and were purified using an Endotoxin-
free Giga Plasmid Kit (Qiagen, Hilden, Germany). Passive lysis
buffer was from Promega (Southampton, UK). Quanti-iT™
PicoGreen® dsDNA reagent and tissue culture media were
obtained from Invitrogen (Paisley, UK). Bioware® B16-F10-luc-
G5 mouse melanoma was obtained from Caliper Life Sciences
(Hopkinton, MA). A431 human epidermoid carcinoma and T98G
human glioblastomawere purchased from the European Collection
of Cell Cultures (Salisbury, UK).
Synthesis and characterization of lactoferrin- and lactoferricin-
bearing DAB dendrimers
Conjugation of lactoferrin and lactoferricin to DAB
Lactoferrin (LF) and lactoferricin (LFC) were conjugated
to generation 3- diaminobutyric polypropylenimine dendrimer
(DAB) in a similar manner to that we previously reported for
the preparation of other conjugates.4,9–12 DAB (24 mg) was
added to lactoferrin or lactoferricin (6 mg) and dimethylsuber-
imidate (12 mg) in triethanolamine HCl buffer (pH 7.4, 2 mL).
The coupling reaction was allowed to take place for 2 h at 25 °Cwhilst stirring. The conjugates were purified by size exclusion
chromatography using a Sephadex G75 column and freeze-dried.
The grafting of lactoferrin and lactoferricin to DAB was assessed
by 1H NMR spectroscopy using a Jeol Oxford NMR AS
400 spectrometer.
Characterization of dendriplex formation
The ability of DNA to form complexes with DAB-LF and
DAB-LFC dendrimers was assessed by PicoGreen® assay,
following the protocol provided by the supplier. PicoGreen®
reagent was diluted 200-fold in Tris-EDTA buffer (10 mM Tris,
1 mMEDTA, pH 7.5) on the day of the experiment. One milliliter
of PicoGreen® solution was added to 1 mL of dendrimer–DNA
complexes prepared at various dendrimer:DNA weight ratios
(20:1, 10:1, 5:1, 2:1, 1:1, 0.5:1, 0:1). The DNA concentration in
the complexes (10 μg/mL) was kept constant during the
experiment. The fluorescence intensity of the complexes was
analyzed at various time points with a Varian Cary Eclipse
Fluorescence spectrophotometer (Palo Alto, CA) (λexc: 480 nm,
λem: 520 nm). Results were represented as percentage of DNA
condensation and compared with those obtained for DAB-DNA
complex (dendrimer:DNA weight ratio 5:1) (n = 4).
DNA condensation ability of DAB-LF and DAB-LFC was
also assessed by agarose gel retardation assay (Supplementary
data). Nanoparticles of DAB-LF and DAB-LFC complexed with
DNA were also visualized by transmission electron
microscopy10 (Supplementary data).
Dendriplex size and zeta potential measurement
Size and zeta potential of DAB-LF and DAB-LFC dendri-
plexes prepared at various dendrimer:DNA weight ratios (20:1,
10:1, 5:1, 2:1, 1:1, 0.5:1, 0:1) were measured by photon
correlation spectroscopy and laser Doppler electrophoresis using
a Zetasizer Nano-ZS (Malvern Instruments, Malvern, UK).
In vitro biological characterization
Cell culture
A431, T98G and B16-F10-luc-G5 cell lines overexpressing
Tf receptors were grown as monolayers in DMEM (for A431 and
T98G cells) or RPMI-1640 medium (for B16-F10-luc-G5 cells)
supplemented with 10% (v/v) fetal bovine serum, 1% (v/v)
L-glutamine and 0.5% (v/v) penicillin–streptomycin. Cells were
cultured at 37 °C in a humid atmosphere of 5% carbon dioxide.
In vitro transfection
Transfection efficacy of the DNA carried by DAB-LF and
DAB-LFC dendrimers was assessed by a β-galactosidase transfec-
tion assay, using a plasmid DNA encoding β-galactosidase. A431,
B16-F10 andT98Gcellswere seeded in quintuplicate at a density of
2 000 cells/well in 96-well plates. After 72 h incubation, the cells
were treated with the DAB-LF and DAB-LFC dendriplexes at the
following dendrimer:DNA weight ratios: 20:1, 10:1, 5:1, 2:1, 1:1,
0.5:1, 0:1. DNA concentration (10 μg/mL)was kept constant for all
the formulations tested. Naked DNA served as a negative control;
DAB-DNA (dendrimer:DNAweight ratio 5:1) served as a positive
control. After 72 h incubation, cells were lysed with 1× passive
lysis buffer (50 μL/well) during 20 min. The cell lysates were
then analyzed for β-galactosidase expression.13 Briefly, 50 μL
of the assay buffer (2 mM magnesium chloride, 100 mM
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200 mM sodium phosphate buffer, pH 7.3) was added to each well
containing the lysates. After 2 h incubation at 37 °C, the
absorbance of the samples was read at 405 nm with a plate reader
(Thermo Lab Systems, Multiscan Ascent, UK).
Cellular uptake
Imaging of the cellular uptake of the DNA carried by DAB-
LF and DAB-LFC was carried out by confocal microscopy.
Plasmid DNA encoding β-galactosidase was labeled with the
fluorescent probe Cy3 using a Label IT® Cy3 Nucleic Acid
Labeling kit, as described by the manufacturer. A431, B16-F10
and T98G cells were seeded on coverslips in 6-well plates
(104 cells/well) and grown at 37 °C for 24 h. They were then
incubated for 24 h with Cy3-labeled DNA (2.5 μg DNA/well)
complexed to DAB-LF, DAB-LFC and DAB (dendrimer:DNA
weight ratios of 2:1 for DAB-LF and DAB-LFC, 5:1 for
DAB).11,14 Control slides were treated with naked DNA. The
cells were then washed three times with PBS and fixed with
methanol for 10 min. DAPI was used to stain the nuclei and the
cells were examined using a Leica TCS SP5 confocal
microscope. DAPI was excited with the 405 nm laser line
(bandwidth: 415-491 nm), whereas Cy3 was excited with the
543 nm laser line (bandwidth: 550-620 nm).
The mechanisms involved in the cellular uptake of DNA
complexed to DAB-LF and DAB-LFC dendriplexes were
investigated by treatment with uptake inhibitors and free Tf
(Supplementary data).
In vitro anti-proliferative activity
Anti-proliferative activity of DAB-LF and DAB-LFC
complexed with a TNFα expression plasmid was assessed in
A431, B16-F10 and T98G cancer cell lines. The cells were
seeded in quintuplicate at a density of 2000 cells/well in 96-well
plates 72 h before treatment. Following seeding, they were
incubated for 72 h with the DNA formulations at final
concentrations of 1.28 × 10−3 to 100 μg/mL. Anti-proliferative
activity was evaluated by measuring the growth inhibitory
concentration for 50% of the cell population (IC50) in an MTT
assay. Absorbance was measured at 570 nm using a plate reader.
Dose–response curves were fitted to percentage absorbance
values to obtain IC50 values (three independent experiments,
with n = 5 for each concentration level).
In vivo study
The in vivo experiments described below were approved by
the local ethics committee and performed in accordance with the
UK Home Office regulations.
Biodistribution of gene expression
A431 cancer cells in exponential growth were subcutaneously
implanted to both flanks of female immunodeficient BALB/c
mice (1 × 106 cells per flank). When tumors became palpable,
vascularized and reached a diameter of 5 mm, the mice were
treated with a single intravenous injection of DAB-LF,
DAB-LFC and DAB dendrimers carrying β-galactosidase
expression plasmid (50 μg of DNA). They were sacrificed
24 h after injection and their organs were removed, frozen in
liquid nitrogen, before being analyzed.13In vivo tumoricidal activity
A431 and B16-F10-luc-G5 cells were subcutaneously
implanted to the mice as described above. The mice bearing
vascularized, palpable tumors were treated by intravenous
injection of DAB-LF and DAB-LFC dendrimers complexed
with TNFα expression plasmid or with a non-therapeutic
plasmid encoding β-galactosidase, the non-targeted DAB
dendrimer carrying TNFα expression plasmid, and naked
DNA (50 μg of DNA) once daily for 10 days. The weight of
the mice was measured every day as a surrogate marker of
toxicity and tumor volume was determined by caliper measure-
ments (volume = d3 × π/6). Results were expressed as relative
tumor volume and responses classified analogous to Response
Evaluation Criteria in Solid Tumors (RECIST).15
Statistical analysis
Results were expressed as means ± standard error of the
mean. Statistical significance was assessed by one-way analysis
of variance and Tukey multiple comparison post-test (Minitab®
software, State College, PE). Differences were considered
statistically significant for P values lower than 0.05.Results
Synthesis and characterization of lactoferrin- and lactoferricin-
bearing DAB dendrimers
Conjugation of lactoferrin and lactoferricin to DAB
The synthesis of DAB-LF and DAB-LFC was confirmed by
1H NMR (Supplementary Figure 1).
Characterization of dendriplex formation
DAB-LF and DAB-LFC were able to condense more than
80% and 90% of the DNA, respectively, at dendrimer:DNA
weight ratios of 2:1 or higher (Supplementary Figure 2). DNA
condensation occurred almost instantaneously and was found to
be stable over at least 24 h. It increased with increasing weight
ratios and was almost complete at a dendrimer:DNA weight ratio
of 20:1 for DAB-LFC dendrimer. The DNA condensation
observed for dendrimer:DNA weight ratios of 2:1 or higher was
much higher than that observed for the unmodified dendrimer,
which was of 60% at its best and decreasing with time.
A gel retardation assay confirmed the DNA condensation by
DAB-LF and DAB-LFC dendrimers (Supplementary Figure 3).
The formation of spherical nanoparticles of DAB-LF and
DAB-LFC complexed to DNA was also demonstrated by
electron microscopy (Supplementary Figure 4).
Dendriplex size and zeta potential measurement
DAB-LF and DAB-LFC dendriplexes displayed average
sizes less than 300 nm, at all weight ratios tested (Supplementary
Figure 5). The increase of dendrimer:DNA weight ratios did not
have a significant impact on the dendriplexes size. Among the
two tested targeted dendrimers, DAB-LF dendriplex at a
dendrimer:DNA ratio of 2:1 was found to be the largest, with an
average size of 260 ± 18 nm. In contrast, DAB-LF dendriplex at a
dendrimer:DNA ratio of 0.5:1 was the smallest, with an average
size of 208 ± 15 nm. The conjugation of LF and LFC to DAB led
Figure 1. Transfection efficacy of DAB-LF and DAB-LFC dendriplexes
at various dendrimer:DNA weight ratios in A431 (A), B16-F10 (B) and
T98G cells (C). Results are expressed as the mean ± SEM of three replicates
(n =15). *P b 0.05 vs. the highest transfection ratio.
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dendriplexes compared to the unmodified DAB dendriplex, which
had an average size of 196 nm (polydispersity index: 0.683).10
Zeta potential experiments demonstrated that DAB-LF and
DAB-LFC dendriplexes were bearing a positive surface charge at
all dendrimer:DNA weight ratios. The zeta potential values of
DAB-LF dendriplex reached their maximum (35 ± 2 mV) at a
weight ratio of 2, before decreasing with increasing weight ratios
and finally reaching their minimum (23 ± 1 mV) at a weight ratio
of 20. The zeta potential values of DAB-LFC followed a similar
pattern, namely reaching a maximum (33 ± 1 mV) at a weight
ratio of 1 and then decreasingwith increasingweight ratios to attain
the same value as for DAB-LF dendriplex (23 ±6 mV at a weight
ratio of 20). The conjugation of LF and LFC to DAB increased the
overall positive charge of the dendriplexes compared to non-
targeted DAB-DNA (6 mV)10 for weight ratios over 2:1.
In vitro biological characterization
In vitro transfection
The treatment of A431, B16-F10 and T98G cells with DAB-
LF and DAB-LFC dendriplexes resulted in an increase in gene
expression on all the tested cell lines for some dendrimer:DNA
ratios.
The highest transfection level after treatment with DAB-LF
and DAB-LFC dendriplexes was obtained at a dendrimer:DNA
weight ratio of 2:1 in A431, B16-F10 and T98G cells (Figure 1).
At this ratio, in A431 cells, treatment with DAB-LFC
dendriplex led to the highest transfection (4.96 × 10−3 ±
0.19 × 10−3 U/mL), which was about 1.4-fold higher than that
observed with DAB-LF dendriplex (3.45 × 10−3 ± 0.10 × 10−3
U/mL) (P b 0.001) (Figure 1, A).
By contrast, the highest transfection in B16-F10 cells
was obtained after treatment with DAB-LF dendriplex
(12.07 × 10−3 ± 0.07 × 10−3 U/mL and 11.01 × 10−3 ±
0.12 × 10−3 respectively for DAB-LF and DAB-LFC dendri-
plexes) (Figure 1, B).
In T98G cells as well, the highest transfection resulted
from the treatment of the cells with DAB-LF dendriplex
(5.71 × 10−3 ± 0.24 × 10−3 U/mL), which was about 1.2-fold
higher than that of DAB-LFC dendriplex (4.67 × 10−3 ±
0.16 × 10−3 U/mL) (P b 0.01).
The conjugation of LF and LFC to DAB at their optimal
dendrimer:DNA ratio led to an improved transfection compared to
unconjugated DAB on all tested cell lines. Gene expression
following treatment with DAB-LF dendriplex was respectively
1.2-fold, 5.6- fold and 1.8-fold higher than following treatment
with DAB dendriplex on A431, B16-F10 and T98G cells
(2.83 × 10−3 ± 0.07 × 10−3 U/mL on A431, 2.13 × 10−3 ±
0.06 × 10−3 U/mL on B16-F10, 3.12 × 10−3 ± 0.17 × 10−3 U/mL
on T98G cells (P b 0.001)). Following treatment with DAB-LFC
dendriplex, it was respectively 1.7-fold, 5.1-fold and 1.5-fold
higher than that of DAB-DNA on A431, B16-F10 and T98G
cells (P b 0.001).
Cellular uptake
The cellular uptake of Cy3-labeled DNA carried by DAB-LF and
DAB-LFCwas qualitatively confirmed in the three cancer cell lines by
confocal microscopy (Figure 2). Cy3-labeled DNAwas disseminatedin the cytoplasm after treatment with all DAB formulations in A431,
B16-F10 and T98G cells. However, the DNA uptake appeared to be
more pronounced in A431 and T98G cells treated with DAB-LF and
DAB-LFC dendriplexes. B16-F10 cells treated with DAB-LFC
dendriplex also appeared to be slightly more fluorescent than the cells
Figure 2. Confocal microscopy imaging of the cellular uptake of Cy3- labeled DNA (2.5 μg/well) either complexed with DAB-LF, DAB-LFC, DAB or in
solution, after incubation for 24 h with A431 (left), B16-F10 (middle) and T98G cells (right). Blue: nuclei stained with DAPI (excitation: 405 nm laser line,
bandwidth: 415-491 nm), green: Cy3-labeled DNA (excitation: 543 nm laser line. bandwidth: 550-620 nm) (Bar: 10 μm).
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naked DNA did not show any Cy3-derived fluorescence.
The cellular uptake of Cy3-labeled DNA complexed to
DAB-LF was inhibited by phenylarsine oxide and free Tf, but
not by filipin and colchicine (Supplementary Figure 6). By
contrast, the uptake of DAB-LFC dendriplex was not inhibited
by any of the inhibitors at the tested concentrations.
In vitro anti-proliferative activity
The conjugation of LF and LFC to DAB led to a significant
increase of in vitro anti-proliferative activity in the three tested
cell lines. In A431 cells, the increase was respectively of 3.5-fold
and 2.6-fold for DAB-LF and DAB-LFC dendriplexes compared
to the unmodified DAB dendriplex (IC50 of 2.68 ± 0.63 μg/mL,
3.66 ± 0.22 μg/mL respectively for DAB-LF and DAB-LFCdendriplexes, 9.47 ± 1.15 μg/mL for unmodified DAB dendri-
plex) (Table 1). In B16-F10 cells, it was of 2.5-fold and 3.3-fold
for DAB-LF and DAB-LFC dendriplexes compared to the
unmodified DAB dendriplex (IC50 of 1.88 ± 0.15 μg/mL,
1.44 ± 0.25 μg/mL respectively for DAB-LF and DAB-LFC
dendriplexes, 4.72 ± 0.32 μg/mL for unmodified DAB dendri-
plex). In T98G cells, however, the increase was at its highest, by
4.8-fold and 5.9-fold for DAB-LF and DAB-LFC dendriplexes
compared to DAB dendriplex (IC50 of 6.20 ± 0.71 μg/mL,
5.01 ± 0.48 μg/mL respectively for DAB-LF and DAB-LFC
dendriplexes, 29.84 ± 2.79 μg/mL for unmodified DAB den-
driplex). By contrast, uncomplexed DAB-LF, DAB-LFC and
naked DNA did not exert any cytotoxicity to the cells at the
tested concentrations, thus raising the hypothesis that the
conjugation of LF and LFC to DAB may hamper their intrinsic
anti-cancer activity.
Table 1
Anti-proliferative efficacy of TNFα-encoding DNA complexed with
DAB-LF, DAB-LFC and DAB in A431, B16-F10 and T98G cells,
expressed as IC50 values (n = 15).
IC50 (μg/mL) (mean ± SEM)
Formulation A431 B16F10 T98G
cplx DAB-LF 2.68 ± 0.63 1.88 ± 0.15 6.20 ± 0.71
cplx DAB-LFC 3.66 ± 0.22 1.44 ± 0.25 5.01 ± 0.48
cplx DAB 9.47 ± 1.15 4.72 ± 0.32 29.84 ± 2.79
DAB-LF only N100 N100 N100
DAB-LFC only N100 N100 N100
DAB only N100 N100 N100
DNA only N100 N100 N100
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Biodistribution of gene expression
The intravenous administration of control DAB dendriplex
led to gene expression mainly in the liver (28.6 ± 3.3 mU
β-galactosidase per organ) followed by the tumor (23.3 ± 0.5 mU
β-galactosidase per organ) (Figure 3). By contrast, the
conjugation of LF and LFC to DAB significantly increased by
more than 1.3-fold the gene expression in the tumor (respectively
31.9 ± 1.2 and 33.9 ± 1.5 mU β-galactosidase in the tumor for
DAB-LF and DAB-LFC dendriplexes (P b 0.001)), while
decreasing the β-galactosidase amount in the liver by 2.2-
fold following treatment with DAB-LF dendriplex (12.8 ±
2.1 mU β-galactosidase per organ, P b 0.001) and by 1.6-fold
following treatment with DAB-LFC dendriplex (17.4 ± 3.7 mU
β-galactosidase per organ, P b 0.001). The β-galactosidase
amounts in the heart were also reduced to less than 5 mU
β-galactosidase per organ. In the spleen and the kidneys, gene
expression reached levels similar to those observed following
treatment with non-conjugated DAB dendriplex.
In vivo tumoricidal activity
The intravenous administration of DAB-LF, DAB-LFC and
DAB complexed to TNFα expression plasmid resulted in tumor
regression of A431 tumors (Figure 4, A). This effect was
maintained for the whole duration of the experiment (30 days).
By contrast, tumors treated with naked DNA or with the
dendrimers complexed to a non-therapeutic DNA grew steadily
at a growth rate close to that observed for untreated tumors.
Treatment of the B16-F10 tumors with the 3 dendriplex
formulations led to a different pattern, characterized by a high
variability of response to treatment within a same group and an
overall slowdown of tumor growth compared to naked DNA
treatment (Figure 5, A).
No apparent signs of toxicity or weight loss were observed
during the experiment, thus showing the good tolerability of the
treatments by the mice (Figures 4, B and 5, B).
On the last day of the experiment, 60% of A431
tumors treated with DAB-LF and DAB-LFC dendriplexes had
completely disappeared, which is an improvement compared
to the 40% of A431 tumors disappearing following treatment
with DAB dendriplex (Figure 4, C). The remaining A431
tumors treated by these 3 dendriplexes formulations showed a
partial response.Treatment of B16-F10 tumors with DAB-LF dendriplex led
to 40% tumor disappearance and 20 % tumor regression
(Figure 5, C). Replacing DAB-LF dendriplex by DAB-LFC
dendriplex led to enhanced results, with 50% tumor disappear-
ance and 20% tumor regression. These results were better
compared to those obtained with control DAB dendriplex, which
resulted in 20% tumor disappearance and 40% tumor regression.
By contrast, all tumors treated with naked DNA, with the
dendrimers complexed to a non-therapeutic DNA or left
untreated were progressive for both tumor types.
This improved therapeutic effect resulted in an extended
survival of 22 days compared to untreated mice, for all A431-
bearing mice treated with targeted or control dendriplexes
(Figure 4, D).
Sixty percent of B16-F10-bearing mice treated with DAB-LF
and DAB-dendriplexes had their life extended by 24 days
compared to untreated mice. This enhanced survival is
similar that that observed following treatment with DAB-LFC
dendriplex, but the percentage of surviving animals in that
case increased to 80% (Figure 5, D). Treatment with naked
DNA or with the dendrimers complexed to a non-therapeutic
DNA did not extend the survival of the animals compared to
untreated mice.Discussion
The use of gene therapy for the treatment of remote cancer
and metastasis is limited by the inability of the therapeutic genes
to specifically reach their target following intravenous admin-
istration, without secondary effects to healthy tissues. In order to
overcome this issue, we hypothesized that the conjugation of
DAB dendrimer to lactoferrin and lactoferricin, promising
tumor-targeting ligands of the transferrin family that have
intrinsic anti-tumoral activity and whose receptors are abun-
dantly expressed on cancer cells, would improve the delivery of
therapeutic DNA to cancer cells, resulting in better therapeutic
efficacy in vitro and in vivo.
The conjugation of LF and LFC to DAB did not affect the
ability of the dendrimer to complex DNA. An excess of
dendrimer was however required to ensure efficient DNA
condensation. Variations in the sensitivity of the nucleic acid
stains used in the PicoGreen assay and the gel retardation assay
could be responsible of the condensation discrepancy observed
in these two assays for the dendriplexes at a dendrimer:DNA
weight ratio of 1:1.
DAB-LF and DAB-LFC dendriplexes displayed sizes that
should theoretically allow extravasation across tumor
vasculature.16 They carried positive charges, higher than those
of non-targeted DAB-DNA for weight ratios over 2:1. This zeta
potential increase is most likely due to the presence of the
positively charged amino acids of LF and LFC. It would
eventually lead to an increase of the electrostatic interactions of
the dendriplexes with negatively charged cellular membranes,
resulting in an improved cellular uptake through international-
ization mechanisms.17 DAB-LF and DAB-LFC therefore have
the required physicochemical properties for being efficient gene
delivery systems.
Figure 3. Biodistribution of gene expression after a single intravenous administration of DAB-LF, DAB-LFC and DAB dendriplexes (50 μg DNA
administered). Results were expressed as milliunits β-galactosidase per organ (n = 5). *P b 0.05: highest gene expression treatment vs. other treatments for
each organ.
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conjugation of LF and LFC to DAB led to an enhanced
transfection compared to unconjugated DAB on all the tested cell
lines. The increased β-gal expression following treatment with
DAB-LF and DAB-LFC at a dendrimer:DNA ratio of 2 most
likely resulted from the higher cellular uptake of these
dendriplexes at this ratio, as there is a strong correlation between
cellular uptake and positive charge density of dendriplexes.18
The cellular uptake of Cy3-labeled DNA complexed to
DAB-LF was inhibited by free Tf and by phenylarsine oxide,
which is an inhibitor of clathrin-mediated endocytosis necessary
for receptor-mediated endocytosis,19 but not by filipin and
colchicine, both involved in non-specific endocytosis
processes.20,21 These results therefore confirm the involvement
of Tf receptor-mediated endocytosis in the cellular internaliza-
tion of DNA complexed to DAB-LF.
Our cellular uptake results were in line with previous data
obtained by Wei and colleagues,22 who demonstrated that the
uptake of LF-conjugated, coumarin- and DiR-loaded liposomes
was much higher than that of unconjugated liposomes in HepG2
human hepatoma cells. This outcome was also confirmed by
Chen et al,23 who revealed that doxorubicin encapsulated in LF-
bearing liposomes was more efficiently taken up by C6 glioma
cells compared to other formulations. Our transfection results are
in accordance with those obtained by Elfinger and colleagues in
an experiment done with polyethylenimine (PEI) conjugated to
LF.24 They demonstrated that LF-PEI polyplex exhibited a
luciferase gene expression 5-fold higher than that of PEI
polyplex in cells overexpressing LF receptors. Furthermore, we
could not find any studies describing the transfection efficacy of
LF-and LFC-bearing gene delivery systems in cancer cells to
allow a comparison with our results. LF has been previously used
as part of a gene therapeutic system against cancer, but as
therapeutic LF cDNA instead of cancer-targeting moiety.25–27
The conjugation of LF and LFC to DAB increased the in vitro
anti-proliferative activity of the dendriplex in the three tested celllines. These results may be attributed to the improved
transfection efficacy when treated with LF- and LFC-bearing
DAB dendriplexes. DAB-LF and DAB-LFC dendriplexes were
the most efficacious treatments on B16-F10 cells, probably as a
result of their highest transfection efficacy on the same cell line.
However, as for the transfection efficacy experiments, the lack of
studies describing the anti-proliferative efficacy of LF- and LFC-
bearing gene delivery systems in cancer cells prevented
comparison with our results.
In vivo, DAB-LF and DAB-LFC dendriplexes administered
intravenously resulted in an increased gene expression in
subcutaneous tumors, while decreasing gene expression in the
liver and the heart. Transferrin receptors are expressed in a range
of cancer cells, but also on rapidly growing normal cells. The
combination of active targeting, based on the use of ligands such
as LF and LFC, and passive targeting, based on the accumulation
of particulate delivery systems due to the enhanced permeability
and retention,28 resulted in a tumor-selective targeting strategy.
Similar improvements have been obtained by Wei et al22 when
using LF-bearing PEGylated liposomes for hepatocellular
carcinoma targeting. The authors demonstrated that the accu-
mulation of DiR in tumors was significantly increased after the
conjugation of LF to the PEGylated liposomes, whereas
expression in the lungs and the other organs was reduced
compared to the non-targeted liposomes.
The predominant gene expression in the tumor compared to
the other organs is comparable to the gene expression pattern
previously reported following intravenous administration of
DAB-Tf dendriplex.4 However, when using Tf instead of LF and
LFC as tumor targeting moieties, gene expression in the tumor
was slightly higher (more than 35 mU/organ) than with LF or
LFC. In addition, the β-galactosidase amounts in spleen, kidneys
and liver were further decreased compared to those observed
when using LF and LFC. DAB-LF and DAB-LFC therefore have
the potential to deliver and express their carried DNA to remote
tumors or metastases unsuitable for intratumoral treatments, but
Figure 4. (A) Tumor growth studies in a mouse A431 xenograft model after intravenous administration of DAB-LF dendriplex carrying plasmid DNA encoding
TNFα (50 μg/injection) (green), DAB-LFC dendriplex (blue), DAB dendriplex (orange), DAB-LF dendriplex carrying a non-therapeutic DNA encoding
β-galactosidase (pale green), DAB-LFC dendriplex carrying a non-therapeutic DNA encoding β-galactosidase (pale blue), naked DNA (red) and untreated
tumors (back) (n = 10).(B) Variations of the animal body weight throughout the treatment (Color coding as in (A)).(C) Overall tumor response to treatments at
the end of the study.(D) Time to disease progression. The Y axis gives the proportion of surviving animals over time. Animals were removed from the study once
their tumor reached 11 mm diameter (Color coding as in (A)).
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targeting gene delivery systems.
This communication presents evidence that novel intravenously
administered DAB-LF and DAB-LFC dendriplexes encoding
TNFα led to tumor regression and even complete tumor
suppression in some cases. In this study, DAB-LF and DAB-LFC
have been shown to be able to increase the level of gene expression
in tumors and the therapeutic efficacy compared to DAB
dendriplex, resulting in complete tumor suppression of 40% of
the A431 tumors and up to 50% of the B16-F10 tumors. Other
researchers have already reported the ability of LF to target tumorsin vivo,22 but did not assess the therapeutic efficacy of their delivery
system yet. As far as we know, LF and LFC have been widely
studied for their intrinsic anti-cancer properties, but have not been
used so far as targeting moieties on a gene therapeutic system.
In the A431 xenograft model, the therapeutic effect of DAB-
LF and DAB-LFC dendriplexes encoding TNFα was more
pronounced than that obtained with B16-F10 tumors, contrarily
to what was observed in our anti-proliferative assay in vitro. This
could be explained by the fact that TNFα exerts its potent
cytotoxic effects on tumors in vivo via the death receptor-
dependent apoptotic pathway, but also via its anti-angiogenic
Figure 5. As in Figure 4 in a mouse B16-F10 model.
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actually highlights the limitation of in vitro experiments for
predicting the anti-cancer outcome of novel therapeutic systems
in vivo.
In conclusion, we have demonstrated that novel intravenously
administered lactoferrin- and lactoferricin-bearing DAB dendri-
plexes resulted in an improved tumor gene expression, while
decreasing non-specific gene expression in the liver. Conse-
quently, the intravenous administration of LF- and LFC-bearing,
TNFα-encoding dendriplexes led to a sustained inhibition of
tumor growth and even tumor suppression for 40% of the A431
tumors and up to 50% of the B16-F10 tumors, with long-term
survival of the animals. In contrast, 100% of the tumors treated
with naked DNA or left untreated were progressive. The animals
did not show any signs of toxicity. These therapeutic effects,together with the lack of toxicity, potentially make lactoferrin-
and lactoferricin-bearing DAB promising gene delivery systems
for intravenous cancer therapy and should be further investigated
to optimize their therapeutic potential.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.nano.2015.04.006.References
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